The stock's overall trend over the past six months has been volatile but negative, with a 6-month price change of -2.81%. It reached a peak near $101 in late December 2025 before a significant correction, including a sharp drop in early February 2026. Short-term performance has been weak, with the stock down 3.07% over the past month and down 12.60% over the past three months. This underperforms the broader market, as indicated by negative relative strength figures of -7.97% over three months. The current price of $84.89 sits near the middle of its 52-week range of $64.84 to $101.79, representing a recovery from recent lows but still significantly below its high. The stock has shown positive relative strength versus the market over the past month (+2.18%), suggesting some stabilization.

Revenue growth has been positive, with Q4 2025 revenue of $2.08 billion representing a 2.46% year-over-year increase. Profitability has improved notably, as the Q4 2025 net margin expanded to 24.95% from 17.49% in Q4 2024, driven by a significant jump in gross margin to 66.92%. Financial health is solid, with a debt-to-equity ratio of 0.81 indicating moderate leverage. The company maintains a strong cash position, with free cash flow over the trailing twelve months of $1.99 billion, supporting shareholder returns through dividends and buybacks. Operational efficiency is robust, with a Return on Equity (ROE) of 14.63% and a Return on Assets (ROA) of 5.06%. The current ratio of 1.01 indicates adequate short-term liquidity to cover obligations.